We develop bone marrow-targeted LNPs through marrow-homing lipid design, targeting ligand engineering, and stealth surface modification, providing end-to-end support from lipid synthesis and formulation to characterization and cell-specific delivery evaluation.
Bone marrow-targeted LNPs are engineered to deliver nucleic acids and other payloads to hematopoietic stem and progenitor cells, malignant marrow cells, marrow endothelium, and immune-cell populations within the marrow niche. Conventional LNPs are rapidly sequestered by the liver and the mononuclear phagocyte system, while the sinusoidal blood–bone marrow barrier and low bone perfusion further limit marrow access. Marrow-targeted formulations address these barriers through chemically defined ionizable lipid libraries, bone-mineral-affinity lipid motifs, displayed targeting ligands, and "don't eat me" surface cloaking that together shift biodistribution away from hepatic clearance and toward productive delivery inside the marrow.
BOC Sciences provides integrated targeted LNP development for bone marrow applications, covering marrow-homing lipid design and synthesis, ligand conjugation, payload encapsulation, formulation and process optimization, and cellular and in vivo evaluation. We support customized LNPs for mRNA, siRNA, miRNA, plasmid DNA, and genome-editing research, with the targeting strategy matched to the intended marrow cell population and administration route.
Lipid Nanoparticle Delivery to Bone Marrow DiagramBone marrow delivery requires more than increasing nanoparticle accumulation in a target organ. Formulation properties, vascular access, cell-surface recognition, intracellular trafficking, and payload activity all influence the final delivery outcome. BOC Sciences integrates lipid chemistry, ligand engineering, nanoparticle formulation, and biological evaluation to develop LNPs for different bone marrow delivery objectives. Projects can begin with an existing formulation, a candidate targeting molecule, or a defined target-cell population.
We investigate how ionizable lipid structures and supporting lipid components influence serum protein interactions, tissue distribution, and bone marrow cell uptake. Lipid composition is optimized according to the intended delivery objective, whether broad marrow distribution or preferential delivery to selected hematopoietic populations.
We develop antibody- and peptide-functionalized LNPs to improve interactions with selected hematopoietic or malignant cell populations. Target recognition depends on ligand identity, receptor accessibility, conjugation chemistry, surface orientation, and ligand density. These variables are evaluated together to establish a functional targeting architecture.
Different payloads require different encapsulation and formulation conditions. We integrate lipid composition, targeting modifications, and payload characteristics to develop formulations that preserve particle integrity and payload activity while maintaining the intended bone marrow delivery properties.
We evaluate candidate LNPs at the particle, cellular, and tissue levels to determine whether improved marrow accumulation translates into functional delivery to the intended cell population. Evaluation plans are selected according to the payload, target-cell type, and biological research objective.
Bone marrow-targeted LNPs can be developed through intrinsic composition engineering or through surface display of antibodies, peptides, and evasion signals. BOC Sciences supports lipid design and synthesis, ligand conjugation, LNP formulation, and delivery evaluation. The following strategies represent the main design routes currently used in marrow-targeting research.
Marrow homing can be achieved without any surface ligand by engineering the lipid composition itself. In reported screening programs, chemically diverse ionizable lipid libraries—varying headgroup, linker, and tail architecture—were formulated into candidate LNPs and evaluated for marrow accumulation after intravenous administration.
Research reference: Bone-marrow-homing LNPs delivering editors to at least 14 marrow cell types, including HSCs and leukemic stem cells (Nature, 2025); antibody-free LNP-168 achieving HSC base editing in a humanized sickle-cell model (Nature Biomedical Engineering, 2025).
Antibody-displayed LNPs use surface recognition components to engage markers on hematopoietic stem and progenitor cells. CD117 (c-Kit)-targeted LNPs, conjugated through maleimide-functionalized PEG-lipids, have achieved dose-responsive in vivo HSC transfection with reported levels of approximately 64–90% in marrow cells, supporting both reporter expression and functional gene-modulation studies.
Research reference: Summary of marrow-targeted RNA-LNP strategies, including CD117-targeted systems and their delivery performance (review, 2025).
Peptide ligands provide a compact, chemically defined route to marrow-cell recognition. VLA-4 (α4β1 integrin)-targeted LNPs displaying a modified Leu-Asp-Val tripeptide motif have shown significantly improved bone marrow accumulation and retention, with functional siRNA delivery demonstrated in patient-derived leukemia cells compared with non-targeted controls.
Research reference: VLA-4-targeted LNPs with increased marrow uptake and siRNA delivery to patient-derived leukemia cells (Pharmaceutics, 2023).
Because the marrow niche is dominated by phagocytic and endothelial barriers, combining a targeting ligand with an evasion signal can improve both selectivity and delivery depth. Reported CD47/"don't eat me"-cloaked targeted LNPs reduced macrophage and hepatic uptake and increased targeting efficiency to hematopoietic populations up to three-fold compared with targeted LNPs alone, with an altered protein corona and reduced inflammatory hepatic effects.
Research reference: CD47-cloaked targeted LNPs for cell-specific mRNA delivery and HSC-selective depletion (Cell, 2025).
Share your payload and target-cell requirements. BOC Sciences can help evaluate feasible design options, synthesize relevant components, and build a comparative screening strategy against matched controls.
BOC Sciences develops marrow-targeted LNPs for the payload classes most frequently used in hematopoietic and marrow-niche research. Each payload requires a matched loading strategy, particle design, and functional readout, and we connect marrow-targeting design with payload-specific formulation requirements.
| Payload Type | Supported Uses & Bone Marrow-Targeted LNP Development Considerations | Request Information |
|---|---|---|
| Bone Marrow-Targeted LNP for mRNA | Designed for reporter expression, functional protein expression in HSPC-like models, and transient editor delivery. Development focuses on mRNA integrity, encapsulation efficiency, marrow-cell transfection, and marrow-versus-liver expression ratios, supported by our lipid nanoparticles for mRNA delivery platform. | Inquiry |
| Bone Marrow-Targeted LNP for siRNA and miRNA | Suitable for gene-knockdown studies in hematopoietic, leukemic, and marrow-endothelial models. Development evaluates oligonucleotide loading, target silencing in marrow-relevant cells, and selectivity against hepatic uptake, drawing on our lipid nanoparticles for siRNA delivery experience. | Inquiry |
| Bone Marrow-Targeted LNP for Cas9 mRNA, sgRNA, and Base Editors | Applicable to in vivo genome-editing research in hematopoietic models, where transient editor expression and re-dosing capability are key advantages of LNP delivery. We evaluate co-loading of editor mRNA and guide RNA, editing readouts such as indel and base-conversion frequencies in marrow cell models, and particle consistency, building on our lipid nanoparticles for CRISPR RNP delivery capabilities. | Inquiry |
| Bone Marrow-Targeted LNP for circRNA and saRNA | Designed for payloads requiring strong protection and sustained expression in marrow-associated cells. Development considers payload integrity, encapsulation behavior, particle stability, and expression duration in hematopoietic cell models, supported by our lipid nanoparticles for circRNA delivery platform. | Inquiry |
| Bone Marrow-Targeted LNP for ASO | Suitable for splice-modifying and knockdown oligonucleotide research in hematopoietic cells, where efficient nuclear delivery remains a major bottleneck. Development focuses on oligonucleotide loading, nuclear delivery, and uptake comparison across marrow cell populations, supported by our lipid nanoparticles for ASO delivery services. | Inquiry |
| Bone Marrow-Targeted LNP for Protein and Peptide | Applicable to enzymes, genome-editor proteins, and signaling peptides intended for marrow-cell delivery research. Formulation work emphasizes mild loading conditions, aggregation control, and preserved biological activity, drawing on our protein encapsulation in LNPs experience. | Inquiry |
| Bone Marrow-Targeted LNP for Small Molecule | Designed for hydrophobic, amphiphilic, or ionizable small molecules studied in marrow-niche and hematologic malignancy research. We evaluate drug–lipid compatibility, loading method, retention during surface modification, and release behavior, supported by hydrophobic payload encapsulation in LNPs. | Inquiry |
| Bone Marrow-Targeted LNP for Fluorescent and Tracking Labels | Supports labeled particles used to map marrow accumulation, cell-type-specific localization, and in vivo biodistribution trends between bone compartments and clearance organs, enabled by our tracking-labeled lipid nanoparticles capabilities. | Inquiry |
| Bone Marrow-Targeted LNP for Custom Payload | Developed for unusual payloads, co-delivery systems, or early feasibility studies. We evaluate payload compatibility, loading sequence, marrow-targeting modification route, particle stability, and delivery performance in the agreed marrow cell models. | Inquiry |
Tell us your payload, target marrow cell population, and delivery goal, and BOC Sciences will propose a targeting strategy that fits your project.
Projects can begin with an existing LNP formulation, a candidate targeting ligand, or only a delivery objective. We organize the work into four practical stages and refine the plan as formulation and biological evidence becomes available.

We review the payload class, the intended marrow population—HSCs and progenitors, myeloid or lymphoid subsets, leukemic cells, or marrow endothelium—the administration route, any baseline formulation, and the desired biological readouts. These inputs define the starting materials, comparator models, and screening plan.

We propose candidate ionizable lipids, helper lipid and cholesterol balances, and PEG-lipid or stealth architectures, then select the targeting layer—composition-intrinsic marrow homing, antibody display, or peptide ligands. Ratios are refined through structured LNP lipid ratio optimization services, and each design includes matched non-targeted control LNPs.

Candidates are prepared under controlled mixing conditions, including microfluidic LNP production, and compared for particle size, PDI, zeta potential, ligand density, and payload retention. We adjust composition, ligand input, purification, and buffer exchange, then advance only candidates that meet agreed particle-attribute thresholds.

Selected candidates are evaluated in marrow-relevant cell models using uptake imaging, flow cytometry, and payload-specific endpoints such as reporter expression or gene knockdown. Combined nanoparticle in vivo distribution analysis then compares marrow accumulation against hepatic and splenic exposure, and cell-type-resolved readouts identify which marrow populations are productively transfected. Findings are summarized as a comparative dataset with documented design tradeoffs and suggested next experiments.
A bone marrow-targeted LNP may show favorable particle properties or organ accumulation but still deliver insufficient payload to the intended cells. We investigate formulation, tissue access, receptor recognition, and intracellular trafficking together to identify the limiting step and guide targeted optimization.
Conventional LNPs can show substantial hepatic uptake after systemic administration, leaving a limited fraction available for marrow delivery. Lipid composition, surface properties, and serum protein adsorption all influence this distribution. We compare ionizable lipid structures, PEG-lipid content, and supporting lipid ratios, then assess marrow-to-liver distribution rather than relying only on total tissue signal. Where relevant, serum protein adsorption profiles are also examined to understand formulation-dependent differences in tissue accumulation.
Bone marrow delivery requires nanoparticles to reach the marrow compartment through its vascular interface. Particle size, surface charge, PEG architecture, and interactions with the endothelial barrier can influence tissue access and extravasation. We compare formulation properties and targeting architectures to investigate whether limited delivery results from vascular access, particle retention, or insufficient tissue penetration. Distribution measurements are used to distinguish particles associated with marrow vasculature from those reaching deeper marrow compartments.
Bone marrow accumulation does not necessarily indicate delivery to the intended cell population. HSCs, myeloid cells, lymphocytes, malignant cells, and stromal-associated populations have different surface markers and uptake characteristics. We investigate receptor expression, ligand identity, ligand accessibility, and surface density to improve target-cell recognition. Cell-resolved uptake measurements and functional payload readouts are used to determine whether the selected targeting component improves productive delivery rather than nonspecific particle association.
Even after cellular uptake, LNPs may remain trapped in endosomal compartments or fail to release an active payload into the appropriate intracellular location. This can result in strong particle-associated signals but weak reporter expression, gene silencing, or editing activity. We compare ionizable lipid pKa, lipid packing, helper lipid composition, and intracellular localization to investigate post-uptake limitations. LNP endosomal escape evaluation can help distinguish uptake-related improvements from effective intracellular payload release.
Share your current LNP composition, targeting strategy, payload, and evaluation results. BOC Sciences can help identify the limiting delivery step and develop a focused optimization plan for bone marrow accumulation and functional cellular delivery.
Bone marrow-targeted LNPs provide a delivery approach for research involving hematopoietic stem cells, blood-cell development, hematologic malignancies, and marrow-associated immune and endothelial populations. Their applications depend on the target-cell population, payload function, and degree of cellular selectivity required. BOC Sciences supports customized formulation and evaluation for these research directions.
Tell us your target cell population, payload, and research objective. BOC Sciences can help design, synthesize, formulate, and evaluate bone marrow-targeted LNPs according to your project requirements.
We connect ionizable lipid structure, supporting lipid composition, and serum protein interactions with marrow delivery outcomes. Our design approach considers both composition-driven bone marrow homing and ligand-assisted targeting, helping identify suitable formulation variables for extrahepatic delivery.

Our development capabilities cover antibody and peptide synthesis, lipid-anchor conjugation, linker selection, and surface display optimization. We help match ligand chemistry and presentation to selected receptors, including CD117, CD34, CD38, and VLA-4-associated targeting strategies.
We support the selection and optimization of ionizable lipids, helper phospholipids, cholesterol, and PEG-lipids for different payload classes. From mRNA and siRNA to gene-editing components, oligonucleotides, proteins, and small molecules, formulation conditions are tailored to payload properties and delivery objectives.
Particle characterization, marrow cell uptake, functional payload readouts, and tissue distribution studies are combined in one evaluation strategy. We distinguish organ-level accumulation from cell-specific delivery and functional intracellular release, providing data to guide formulation decisions.
From target-cell definition and lipid design to ligand modification, payload encapsulation, formulation optimization, and biological evaluation, BOC Sciences provides integrated development support. Our project workflow connects material selection with measurable delivery outcomes, helping research teams refine LNP designs through systematic comparison and iterative optimization.
Bone marrow-targeted lipid nanoparticles (LNPs) are designed to improve the delivery of therapeutic or research payloads to bone marrow tissue and its associated cell populations. Unlike conventional LNPs that often accumulate predominantly in the liver, these systems use specialized lipid compositions, targeting ligands, or surface modifications to improve marrow distribution and cellular uptake. Applications include hematopoietic stem cell modification, gene editing, leukemia research, and immune-cell modulation. The development objective is not simply to increase bone marrow accumulation but also to achieve functional payload delivery to the intended cells.
Bone marrow targeting can be achieved through lipid composition engineering or surface functionalization. Composition-engineered LNPs use selected ionizable lipids and supporting components to influence serum protein adsorption and tissue distribution. Antibody-functionalized systems can recognize receptors such as CD117, CD34, or CD38, while peptide-functionalized LNPs can incorporate receptor-binding sequences, including VLA-4-recognizing peptides. Dual-ligand systems combine two targeting components to address marrow localization and specific cell recognition. BOC Sciences supports lipid screening, ligand synthesis, conjugation, and formulation optimization for these different targeting strategies.
Bone marrow-targeted LNPs can be designed for different hematopoietic and marrow-associated cell populations, depending on their lipid composition and targeting architecture. Potential targets include hematopoietic stem cells (HSCs), hematopoietic stem and progenitor cells (HSPCs), myeloid progenitors, B cells, T cells, macrophages, monocytes, endothelial cells, leukemia cells, and malignant plasma cells. CD117 and CD34 are relevant targets for HSC and HSPC delivery, whereas CD38 can support recognition of multiple myeloma cells. Target-cell receptor expression and functional delivery should be evaluated in the selected experimental models.
Bone marrow-targeted LNPs can accommodate multiple payload classes, including mRNA, siRNA, miRNA, antisense oligonucleotides (ASOs), guide RNA, and gene-editing components such as Cas9 mRNA and sgRNA. Other possibilities include circular RNA, self-amplifying RNA, proteins, peptides, and selected small molecules. Co-delivery formulations can also combine complementary payloads, such as mRNA with sgRNA or a small molecule with siRNA. BOC Sciences supports payload-specific formulation development, considering molecular properties, lipid compatibility, encapsulation conditions, particle stability, and functional release requirements.
Evaluation generally combines physicochemical characterization, cellular uptake analysis, functional payload testing, and tissue distribution studies. Particle size, polydispersity index, zeta potential, morphology, encapsulation efficiency, and payload integrity help establish formulation characteristics. Cellular studies can assess uptake in selected HSCs, HSPCs, or malignant cell models using imaging and flow cytometry, followed by reporter expression, gene silencing, or editing measurements. In vivo studies can compare bone marrow accumulation with liver and spleen distribution. Cell-resolved analysis is particularly important because organ-level accumulation alone does not demonstrate successful delivery to the intended cell population.